Press Release: Prosonix : Prosonix' Marketing Authorisation Application for PSX1001 - a Generic Version of GlaxoSmithKline's Flixotide® Evohaler® - Under Assessment in EU

QXFORD, England, September 2, 2014 /PRNewswire/ -- Triggers milestone payment from Mylan  Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for...